Cargando…
Prognostic impact of platinum sensitivity in ovarian carcinoma patients with brain metastasis
BACKGROUND: Brain metastasis (BM) is a rare event in ovarian cancer patients. The current prognostic scores that have been used for other tumors do not account for specific characteristics of ovarian cancer, such as platinum sensitivity. METHODS: This retrospective cohort study examined patients wit...
Autores principales: | da Costa, Alexandre André Balieiro Anastácio, dos Santos, Elizabeth Santana, Cotrim, Deborah Porto, Pandolfi, Natasha Carvalho, Cesca, Marcelle Goldner, Mantoan, Henrique, Sanches, Solange Moraes, Ribeiro, Adriana Regina Gonçalves, de Brot, Louise, Bonvolim, Graziele, Sanematsu, Paulo Issamu, de Souza, Ronaldo Pereira, Maya, Joyce Maria Lisboa, de Souza Castro, Fabrício, da Nogueira Silveira Lima, João Paulo, Chen, Michael Jenwel, Guimarães, Andrea Paiva Gadelha, Baiocchi, Glauco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896587/ https://www.ncbi.nlm.nih.gov/pubmed/31805898 http://dx.doi.org/10.1186/s12885-019-6382-x |
Ejemplares similares
-
Retrospective analysis of the role of cyclin E1 overexpression as a predictive marker for the efficacy of bevacizumab in platinum-sensitive recurrent ovarian cancer
por: Ribeiro, Adriana Regina Gonçalves, et al.
Publicado: (2021) -
The value of PET/CT for cytoreductive surgery selection in recurrent ovarian carcinoma
por: Nunes, Rafael Leite, et al.
Publicado: (2023) -
Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil
por: Cotrim, Deborah Porto, et al.
Publicado: (2019) -
Case Report of Small Cell Carcinoma of the Ovary, Hypercalcemic Type (Ovarian Rhabdoid Tumor) with SMARCB1 Mutation: A Literature Review of a Rare and Aggressive Condition
por: Simões, Maria Fernanda Evangelista, et al.
Publicado: (2022) -
Comparison of dose-dense vs. 3-weekly paclitaxel and carboplatin in the first-line treatment of ovarian cancer in a propensity score-matched cohort
por: Pirolli, Rafaela, et al.
Publicado: (2021)